by Stephen Levin
In this era of evidence-based medicine with its abundance of clinical trials, particularly in cardiology, it’s hard to recall a medical device study that has stirred the pot as much as the COURAGE trial, roiling both clinicians and industry. With more subplots than a Sopranos episode (and some of the intrigue), physicians continue to disagree on the study’s significance, even though it’s been several months since the data were released at the American College of Cardiology (ACC) conference in New Orleans in March. Also see "COURAGE Trial: Bad News Again for Stents at ACC, Or Is It
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?